{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T04:26:15Z","timestamp":1784089575035,"version":"3.55.0"},"reference-count":32,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,10]],"date-time":"2024-12-10T00:00:00Z","timestamp":1733788800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100020948","name":"AstraZeneca Gothenburg","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020948","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JACC: Heart Failure"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1016\/j.jchf.2024.10.020","type":"journal-article","created":{"date-parts":[[2025,2,3]],"date-time":"2025-02-03T19:04:25Z","timestamp":1738609465000},"page":"277-292","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["EuroQol 5-Dimension Questionnaire in Heart\u00a0Failure With Reduced, Mildly Reduced, and Preserved Ejection Fraction"],"prefix":"10.1016","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4484-0979","authenticated-orcid":false,"given":"Mingming","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toru","family":"Kondo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atefeh","family":"Talebi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pardeep S.","family":"Jhund","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5446-9969","authenticated-orcid":false,"given":"Kieran F.","family":"Docherty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian L.","family":"Claggett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muthiah","family":"Vaduganathan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erasmus","family":"Bachus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian F.","family":"Hernandez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolyn S.P.","family":"Lam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felipe A.","family":"Martinez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rudolf A.","family":"de Boer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikhail N.","family":"Kosiborod","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akshay S.","family":"Desai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars","family":"K\u00f8ber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piotr","family":"Ponikowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0691-3359","authenticated-orcid":false,"given":"Marc S.","family":"Sabatine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott D.","family":"Solomon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6317-3975","authenticated-orcid":false,"given":"John J.V.","family":"McMurray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jchf.2024.10.020_bib1","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1053\/euhj.2002.3255","article-title":"Impact of heart failure and left ventricular systolic dysfunction on quality of life: a cross-sectional study comparing common chronic cardiac and medical disorders and a representative adult population","volume":"23","author":"Hobbs","year":"2002","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jchf.2024.10.020_bib2","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1161\/CIRCULATIONAHA.120.050850","article-title":"Health-related quality of life and mortality in heart failure: the Global Congestive Heart\u00a0Failure Study of 23 000 patients from 40 countries","volume":"143","author":"Johansson","year":"2021","journal-title":"Circulation"},{"key":"10.1016\/j.jchf.2024.10.020_bib3","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.jchf.2015.10.015","article-title":"Utility of patient-reported outcome instruments in heart failure","volume":"4","author":"Kelkar","year":"2016","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.jchf.2024.10.020_bib4","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1016\/j.jacc.2020.09.542","article-title":"Interpreting the Kansas City Cardiomyopathy Questionnaire in clinical trials and clinical care: JACC state-of-the-art review","volume":"76","author":"Spertus","year":"2020","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jchf.2024.10.020_bib5","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1007\/s11136-011-9903-x","article-title":"Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L)","volume":"20","author":"Herdman","year":"2011","journal-title":"Qual Life Res"},{"key":"10.1016\/j.jchf.2024.10.020_bib6","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1007\/s00059-022-05123-9","article-title":"Comorbidities in heart failure with preserved ejection fraction","volume":"47","author":"Deichl","year":"2022","journal-title":"Herz"},{"key":"10.1016\/j.jchf.2024.10.020_bib7","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1002\/ejhf.30","article-title":"Co-morbidities in patients with heart failure: an analysis of the European Heart\u00a0Failure Pilot Survey","volume":"16","author":"van Deursen","year":"2014","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jchf.2024.10.020_bib8","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1002\/ejhf.2962","article-title":"Impact of comorbidities on health status measured using the Kansas City Cardiomyopathy Questionnaire in patients with heart failure with reduced and preserved ejection fraction","volume":"25","author":"Yang","year":"2023","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jchf.2024.10.020_bib9","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1002\/ejhf.3263","article-title":"Dapagliflozin and quality of life measured using the EuroQol 5-Dimension questionnaire in patients with heart failure with reduced and mildly reduced\/preserved ejection fraction","volume":"26","author":"Yang","year":"2024","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jchf.2024.10.020_bib10","series-title":"Methods for Analysing and Reporting EQ-5D Data","first-page":"23","article-title":"Analysis of EQ-5D profiles","author":"Devlin","year":"2020"},{"key":"10.1016\/j.jchf.2024.10.020_bib11","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s11136-021-02922-1","article-title":"Combining EQ-5D-5L items into a level summary score: demonstrating feasibility using nonparametric item response theory using an international dataset","volume":"31","author":"Feng","year":"2022","journal-title":"Qual Life Res"},{"key":"10.1016\/j.jchf.2024.10.020_bib12","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jchf.2024.10.020_bib13","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1056\/NEJMoa2206286","article-title":"Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction","volume":"387","author":"Solomon","year":"2022","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jchf.2024.10.020_bib14","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1002\/ejhf.2249","article-title":"Dapagliflozin in heart failure with preserved and mildly reduced ejection fraction: rationale and design of the DELIVER trial","volume":"23","author":"Solomon","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jchf.2024.10.020_bib15","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.jchf.2021.11.006","article-title":"Baseline characteristics of patients with HF with mildly reduced and preserved ejection fraction: DELIVER trial","volume":"10","author":"Solomon","year":"2022","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.jchf.2024.10.020_bib16","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1002\/ejhf.1432","article-title":"A\u00a0trial to evaluate the effect of the sodium-glucose co-transporter 2 inhibitor dapagliflozin on morbidity and mortality in patients with heart failure and reduced left ventricular ejection fraction (DAPA-HF)","volume":"21","author":"McMurray","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jchf.2024.10.020_bib17","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1002\/ejhf.1548","article-title":"The Dapagliflozin and Prevention of Adverse-Outcomes in Heart\u00a0Failure (DAPA-HF) trial: baseline characteristics","volume":"21","author":"McMurray","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jchf.2024.10.020_bib19","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1186\/s12955-020-01368-2","article-title":"Mapping the Minnesota Living With Heart\u00a0Failure Questionnaire (MLHFQ) to EQ-5D-5L in patients with heart failure","volume":"18","author":"Kularatna","year":"2020","journal-title":"Health Qual Life Outcomes"},{"key":"10.1016\/j.jchf.2024.10.020_bib20","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1093\/ehjqcco\/qcab014","article-title":"Predicting the EQ-5D utilities from the Kansas City Cardiomyopathy Questionnaire in patients with heart failure","volume":"7","author":"Thomas","year":"2021","journal-title":"Eur Heart J Qual Care Clin Outcomes"},{"key":"10.1016\/j.jchf.2024.10.020_bib21","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/ehf2.12363","article-title":"Assessing health-related quality of life in heart failure patients attending an outpatient clinic: a pragmatic approach","volume":"6","author":"Gallagher","year":"2019","journal-title":"ESC Heart Fail"},{"key":"10.1016\/j.jchf.2024.10.020_bib22","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1007\/s40273-020-00984-6","article-title":"Health state utilities of patients with heart failure: a systematic literature review","volume":"39","author":"Di Tanna","year":"2021","journal-title":"PharmacoEconomics"},{"key":"10.1016\/j.jchf.2024.10.020_bib23","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1002\/ejhf.3352","article-title":"Geographical variation in patient characteristics and outcomes in heart failure with mildly reduced and preserved ejection fraction","volume":"26","author":"Yang","year":"2024","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jchf.2024.10.020_bib24","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1002\/ejp.2176","article-title":"Prevalence of chronic pain and chronic widespread pain among subjects with heart failure in the general population: the HUNT study","volume":"28","author":"Vikan","year":"2024","journal-title":"Eur J Pain"},{"key":"10.1016\/j.jchf.2024.10.020_bib25","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/j.jpainsymman.2007.11.014","article-title":"Pain and quality of life in hospitalized patients with heart failure","volume":"36","author":"Rust\u00f8en","year":"2008","journal-title":"J\u00a0Pain Symptom Manage"},{"key":"10.1016\/j.jchf.2024.10.020_bib26","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1186\/s12872-022-02864-7","article-title":"Prevalence of pain and its association with quality of life of patients with heart failure in a developing country: findings from a multicenter cross-sectional study","volume":"22","author":"Mhesin","year":"2022","journal-title":"BMC Cardiovasc Disord"},{"key":"10.1016\/j.jchf.2024.10.020_bib27","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/s41687-020-00216-7","article-title":"Evaluation of the usefulness of EQ-5D as a patient-reported outcome measure using the Paretian classification of health change among patients with chronic heart failure","volume":"4","author":"Jonsson","year":"2020","journal-title":"J\u00a0Patient Rep Outcomes"},{"key":"10.1016\/j.jchf.2024.10.020_bib28","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1001\/jamacardio.2023.1342","article-title":"Association of dapagliflozin vs placebo with individual Kansas City Cardiomyopathy Questionnaire components in patients with heart failure with mildly reduced or preserved ejection fraction: a secondary analysis of the DELIVER trial","volume":"8","author":"Peikert","year":"2023","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.jchf.2024.10.020_bib29","doi-asserted-by":"crossref","first-page":"1892","DOI":"10.1002\/ejhf.2652","article-title":"Dapagliflozin and New York Heart Association functional class in heart failure with mildly reduced or preserved ejection fraction: the DELIVER trial","volume":"24","author":"Ostrominski","year":"2022","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jchf.2024.10.020_bib30","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1161\/CIRCULATIONAHA.121.057812","article-title":"Empagliflozin, health status, and quality of life in patients with heart failure and preserved ejection fraction: the EMPEROR-preserved trial","volume":"145","author":"Butler","year":"2022","journal-title":"Circulation"},{"key":"10.1016\/j.jchf.2024.10.020_bib31","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1093\/eurheartj\/ehaa1007","article-title":"Empagliflozin and health-related quality of life outcomes in patients with heart failure with reduced ejection fraction: the EMPEROR-reduced trial","volume":"42","author":"Butler","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jchf.2024.10.020_bib32","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1161\/CIRCULATIONAHA.119.044138","article-title":"Effects of dapagliflozin on symptoms, function, and quality of life in patients with heart failure and reduced ejection fraction: results from the DAPA-HF trial","volume":"141","author":"Kosiborod","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.jchf.2024.10.020_bib33","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1093\/eurheartj\/ehr504","article-title":"The effect of intravenous ferric carboxymaltose on health-related quality of life in patients with chronic heart failure and iron deficiency: a subanalysis of the FAIR-HF study","volume":"34","author":"Comin-Colet","year":"2013","journal-title":"Eur Heart J"}],"container-title":["JACC: Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213177924008540?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213177924008540?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,16]],"date-time":"2025-02-16T14:43:08Z","timestamp":1739716988000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213177924008540"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":32,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["S2213177924008540"],"URL":"https:\/\/doi.org\/10.1016\/j.jchf.2024.10.020","relation":{},"ISSN":["2213-1779"],"issn-type":[{"value":"2213-1779","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"EuroQol 5-Dimension Questionnaire in Heart\u00a0Failure With Reduced, Mildly Reduced, and Preserved Ejection Fraction","name":"articletitle","label":"Article Title"},{"value":"JACC: Heart Failure","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jchf.2024.10.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation.","name":"copyright","label":"Copyright"}]}}